Clinical Advisory Board
Florian Rieder, MD
Clinical Advisory Board Member
Bruce Sands, MD, MS
Clinical Advisory Board Member
Laurent Peyrin-Biroulet, MD, PhD
Clinical Advisory Board Member
David T. Rubin, MD
Clinical Advisory Board Member
Bram Verstockt, MD, PhD
Clinical Advisory Board Member
Vipul Jairath, MBChB, DPhil, MRCP, FRCPC
Clinical Advisory Board Member
Our Technology
Our Pipeline
Sign Up For Alerts
Vipul Jairath, MBChB, DPhil, MRCP, FRCPC
Clinical Advisory Board Member
Dr. Jairath oversees global Medical R&D strategy and operations, including medical operations, medical imaging, precision medicine, medical writing, medical monitoring, biostatistics advisory collaborations, and IBD fellowship programs. He also provides medical leadership for clinical trial design, protocol development, and imaging endpoint strategy.
Dr. Jairath is Professor of Medicine at the Schulich School of Medicine and Dentistry at Western University and holds the John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease (IBD). He completed his medical degree and BSc in Pharmacology at the University of Leeds, earned a DPhil in Clinical Medicine from the University of Oxford, and holds a postgraduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine.
A practicing gastroenterologist specializing in inflammatory bowel disease, Dr. Jairath’s research focuses on clinical therapeutics for IBD, including the design of clinical trials, development and validation of clinical and patient-reported outcome measures, and predictive modeling of treatment response. He has led the development of several novel indices for IBD clinical trials, including the UC-100 and patient-reported outcome measures SIQ-UC and SIQ-CD, and played key roles in the REACT2 and VERDICT clinical trials addressing critical treatment strategies for Crohn’s disease and ulcerative colitis.
Bram Verstockt, MD, PhD
Clinical Advisory Board Member
Dr. Verstockt is an IBD staff physician and professor in the Department of Gastroenterology and Hepatology at University Hospitals Leuven and KU Leuven, Belgium. His clinical and translational research centers on precision medicine in IBD, with a focus on disease heterogeneity, biomarker development, and non-invasive disease monitoring techniques, including intestinal ultrasound and advanced radiologic modalities.
He has played a leading role in international collaborations applying multi-omics, proteomics, and organoid-based platforms to better characterize treatment response and disease behavior in IBD. Dr. Verstockt is also a co-founder of the COLLIBRI proteomics consortium, which advances biomarker discovery and translational research across inflammatory diseases.
Laurent Peyrin-Biroulet, MD, PhD
Clinical Advisory Board Member
Dr. Peyrin-Biroulet is a Professor of Gastroenterology. He is a globally respected authority in Crohn’s disease, ulcerative colitis, intestinal fibrosis and treat-to-target strategies, and has authored more than 1200 peer-reviewed publications. Professor Peyrin-Biroulet was the President of the European Crohn’s and Colitis Organization (ECCO) and Scientific Secretary of the International Organization for the Study of IBD (IOIBD), the two leading international organizations in IBD. Between 2015 and 2023, he was the President of the Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID), a unique national network of French IBD centers. His work has been instrumental in shaping contemporary clinical endpoints, disease-modification strategies and regulatory frameworks for IBD drug development.
Dr. Laurent Peyrin-Biroulet, commented, “Palisade Bio’s focus on intestinal fibrosis and precision targeting of PDE4 biology addresses a major unmet need in IBD, particularly in fibrostenotic Crohn’s disease where therapeutic options remain limited. I look forward to contributing my experience in disease modification and clinical development to help advance this promising program.”
David T. Rubin, MD
Clinical Advisory Board Member
Dr. Rubin is the Joseph B. Kirsner Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago. He also serves as Chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) and Director of the University of Chicago Inflammatory Bowel Disease Center. He is a globally recognized expert in ulcerative colitis, Crohn’s disease, clinical trial design and real-world outcomes research. Dr. Rubin has played a central role in the development and evaluation of numerous approved IBD therapies and previously served as Chair of the Crohn’s & Colitis Foundation’s National Scientific Advisory Committee. He is widely regarded for his ability to bridge clinical research, practice guidelines, and translational science to improve patient outcomes.
Bruce Sands, MD, MS
Clinical Advisory Board Member
Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health System
Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory diseases. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn’s disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn’s disease.
Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.
A leader in several major professional organizations, Dr. Sands has served as the chair of the Clinical Research Alliance of the Crohn’s Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn’s and Colitis Foundation of America, the Crohn’s & Colitis Foundations Henry D. Janowitz Lifetime Achievement Award and Mount Sinai’s Jacobi Medallion. Dr. Bruce Sands is a paid advisory board member for Palisades Bio.
Florian Rieder, MD
Clinical Advisory Board Member
Associate Staff in the Department of Gastroenterology, Hepatology, and Nutrition, as well as an Investigator in the Department of Pathobiology at the Cleveland Clinic
Dr. Rieder is Vice Chair, Co-Director of the IBD section, and Director of the Program for Global Translational IBD at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with IBD with a special emphasis on the field of pathogenesis, prediction and therapy of intestinal fibrosis. Dr. Rieder has published more than 150 articles (h-index 52) and book chapters and has been recognized for his expertise as indicated through invitations to clinical guideline steering committees of the European Crohn’s and Colitis Organization (ECCO). He is lead author of the ECCO guidelines on Ulcerative colitis and lead author of the first ECCO clinical consensus on ‘Diagnosis and Management of Intestinal Fibrosis’. He received multiple international invitations as a speaker, session chair or conference faculty. Dr. Rieder serves as an abstract reviewer for all major GI conferences, he is past associate editor (Clinical and Translational Gastroenterology) and on several editorial boards of medical journals. He is proud of his significant ties to the ECCO, which he served as the chair of Y-ECCO, member of the ECCO operational board, prior Y-ECCO committee member and member of the scientific committee. He is past chair of REACH-IBD and Co-Chair of the Professional Education Committee of the Crohn’s and Colitis Foundation. Dr. Rieder is the leading PI on the international Stenosis Therapy and Research (STAR) Consortium with the goal to build a pathway to test anti-fibrotic medications in Crohn’s disease.